News
Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...
Zacks Investment Research on MSN23h
Pfizer Q2 Earnings Beat Estimates, Oncology Drives Top-Line Growth
Pfizer PFE reported second-quarter 2025 adjusted earnings per share of 78 cents, which comprehensively beat the Zacks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback